MCID: CRV038
MIFTS: 56

Cervical Squamous Cell Carcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Cervical Squamous Cell Carcinoma

MalaCards integrated aliases for Cervical Squamous Cell Carcinoma:

Name: Cervical Squamous Cell Carcinoma 39 12 60 56 15 17 74
Squamous Cell Carcinoma of the Cervix Uteri 12 60
Squamous Cell Carcinoma of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3744
NCIt 51 C4028
ICD10 via Orphanet 35 C53.0 C53.1 C53.8
UMLS via Orphanet 75 C0279671
Orphanet 60 ORPHA213767
UMLS 74 C0279671

Summaries for Cervical Squamous Cell Carcinoma

Disease Ontology : 12 A cervix carcinoma that has material basis in squamous cells of the cervix.

MalaCards based summary : Cervical Squamous Cell Carcinoma, also known as squamous cell carcinoma of the cervix uteri, is related to squamous cell carcinoma and cervical intraepithelial neoplasia. An important gene associated with Cervical Squamous Cell Carcinoma is LOC105379013 (Uncharacterized LOC105379013), and among its related pathways/superpathways are Pathways in cancer and MicroRNAs in cancer. The drugs Cisplatin and Epoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include cervix, uterus and lymph node, and related phenotypes are digestive/alimentary and neoplasm

Related Diseases for Cervical Squamous Cell Carcinoma

Diseases related to Cervical Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.2 CDH1 CDKN2A CTNNB1 DAPK1 MKI67 SERPINB3
2 cervical intraepithelial neoplasia 30.9 CDKN2A KRT8 MKI67
3 adenocarcinoma 30.8 CDH1 CDKN2A CTNNB1 TP53
4 keratinizing squamous cell carcinoma 30.5 CDKN2A TP53
5 papilloma 30.4 CDKN2A KRT8 TP53 TP63
6 basaloid squamous cell carcinoma 30.4 CDKN2A KRT8 TP53
7 adenosquamous carcinoma 30.3 KRT8 TP53 TP63
8 in situ carcinoma 30.3 CDH1 CDKN2A TP53
9 cervical adenocarcinoma 30.3 CDKN2A RASSF1 TP53
10 uterine carcinosarcoma 30.2 CDH1 CTNNB1 TP53
11 transitional cell carcinoma 30.2 CDH1 CDKN2A KRT8 TP53
12 endometrial adenocarcinoma 30.1 CDKN2A CTNNB1 MKI67 TP53
13 cervical cancer 29.2 CDH1 CDKN2A CTNNB1 DAPK1 RASSF1 SERPINB3
14 microinvasive cervical squamous cell carcinoma 12.7
15 cervical verrucous carcinoma 11.3
16 cervical basaloid squamous cell carcinoma 11.3
17 cervical keratinizing squamous cell carcinoma 11.3
18 cervical lymphoepithelioma-like carcinoma 11.3
19 cervix carcinoma 10.8
20 brain ependymoma 10.4 MKI67 TP53
21 cerebral convexity meningioma 10.4 CDH1 TP53
22 bladder squamous cell carcinoma 10.4 CDKN2A TP53
23 adult hepatocellular carcinoma 10.4 CTNNB1 TP53
24 gallbladder adenoma 10.4 CDKN2A CTNNB1
25 large intestine adenocarcinoma 10.4 CDH1 CTNNB1
26 ameloblastic carcinoma 10.4 CDKN2A MKI67 TP63
27 spitz nevus 10.4 CDKN2A MKI67 TP53
28 endometrial mucinous adenocarcinoma 10.4 CDKN2A MKI67
29 benign breast phyllodes tumor 10.3 MKI67 TP63
30 goblet cell carcinoid 10.3 CDH1 CTNNB1
31 tonsil cancer 10.3 CDH1 CDKN2A TP53
32 pre-malignant neoplasm 10.3 CDH1 CDKN2A TP53
33 laryngeal disease 10.3 CDH1 CDKN2A TP53
34 bladder carcinoma in situ 10.3 CDKN2A TP53
35 calcifying epithelial odontogenic tumor 10.3 KRT8 TP53
36 actinic keratosis 10.3 CDKN2A TP53 TP63
37 hidradenocarcinoma 10.3 MKI67 TP53 TP63
38 inverted papilloma 10.3 CDKN2A MKI67 TP53
39 epstein-barr virus-associated gastric carcinoma 10.3 CDH1 CDKN2A CTNNB1
40 polymorphous low-grade adenocarcinoma 10.3 CTNNB1 MKI67 TP63
41 bladder disease 10.3 CDH1 CDKN2A TP53
42 scrotal carcinoma 10.3 CDKN2A TP53
43 vulva squamous cell carcinoma 10.3 CDKN2A SERPINB3 TP53
44 vulvar disease 10.3 CDKN2A SERPINB3 TP53
45 laryngeal squamous cell carcinoma 10.3 CDH1 CDKN2A TP53
46 oral cancer 10.3 CDH1 CDKN2A TP53
47 embryonal sarcoma 10.3 CTNNB1 MKI67 TP53
48 cell type benign neoplasm 10.3 CDKN2A CTNNB1 TP53
49 adenoid squamous cell carcinoma 10.3 CDH1 KRT8
50 vulva cancer 10.3 CDKN2A SERPINB3 TP53

Graphical network of the top 20 diseases related to Cervical Squamous Cell Carcinoma:



Diseases related to Cervical Squamous Cell Carcinoma

Symptoms & Phenotypes for Cervical Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Cervical Squamous Cell Carcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 CDH1 CDKN2A CTNNB1 KRT8 RASSF1 TP53
2 neoplasm MP:0002006 9.43 CDH1 CDKN2A CTNNB1 RASSF1 TP53 TP63
3 no phenotypic analysis MP:0003012 9.17 CDH1 CDKN2A CTNNB1 MKI67 OSMR TP53

Drugs & Therapeutics for Cervical Squamous Cell Carcinoma

Drugs for Cervical Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
2 Epoetin alfa Phase 4,Phase 3 113427-24-0
3 Hematinics Phase 4,Phase 3
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
6
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 123948-87-8, 119413-54-6 60700
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
8
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
9
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
10
Vinblastine Approved Phase 3 865-21-4 13342 241903
11
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
12
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
13
Ifosfamide Approved Phase 3 3778-73-2 3690
14
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
15
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
16
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
18
Tirapazamine Investigational Phase 3,Phase 2,Phase 1 27314-97-2
19 Antimitotic Agents Phase 3,Phase 2,Phase 1
20 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antiviral Agents Phase 3,Phase 2,Phase 1
25 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
26 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
27 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antibodies Phase 3,Phase 2,Phase 1
29 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
30 Mitogens Phase 3,Phase 2,Phase 1
31 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
32 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
33 Immunoglobulins Phase 3,Phase 2,Phase 1
34 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
35 Immunoglobulin G Phase 3,Phase 2,Phase 1
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antimetabolites Phase 3,Phase 2,Phase 1
38 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
39 Alkylating Agents Phase 3,Phase 2
40 Antibiotics, Antitubercular Phase 3,Phase 2,Early Phase 1
41 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
42 Folate Phase 3,Phase 2
43 Vitamin B9 Phase 3,Phase 2
44 Dermatologic Agents Phase 3,Phase 2
45 Antirheumatic Agents Phase 3,Phase 1,Phase 2
46 Folic Acid Antagonists Phase 3,Phase 2
47 Anti-Bacterial Agents Phase 3,Phase 2,Early Phase 1
48 Antineoplastic Agents, Alkylating Phase 3,Phase 2
49
Isophosphamide mustard Phase 3 0
50 Vitamin B Complex Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 129)
# Name Status NCT ID Phase Drugs
1 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
2 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
3 A Randomised Controlled Trial Between Two Different HDR Brachytherapy Schedule in Locally Advanced Carcinoma of Uterine Cervix Completed NCT02765919 Phase 3
4 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
5 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
6 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
7 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
8 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
9 Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
10 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
11 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Active, not recruiting NCT01365156 Phase 3
12 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
13 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
14 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
15 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
16 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
17 A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix Unknown status NCT02482740 Phase 2 Letrozole;tamoxifen
18 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
19 Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer Unknown status NCT00794339 Phase 2 64Cu-ATSM
20 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
21 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
22 Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix Completed NCT00031993 Phase 2 erlotinib hydrochloride
23 Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix Completed NCT00025233 Phase 2
24 Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer Completed NCT00002813 Phase 2 cisplatin;vinorelbine tartrate
25 Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00041093 Phase 2 Docetaxel
26 Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer Completed NCT00005837 Phase 2 oxaliplatin
27 SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00026260 Phase 2 semaxanib
28 Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00016926 Phase 2 capecitabine
29 Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00499031 Phase 2
30 Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application Completed NCT01639625 Phase 2 CIGB300
31 Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer Completed NCT00087126 Phase 2 topotecan hydrochloride
32 Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer Completed NCT02562729 Phase 2
33 S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer Completed NCT00003369 Phase 2 cisplatin;tirapazamine
34 Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005999 Phase 2 arsenic trioxide
35 Docetaxel in Treating Patients With Advanced Cancer of the Cervix Completed NCT00003445 Phase 2 docetaxel
36 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed NCT00389974 Phase 2 sunitinib malate
37 DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix Completed NCT00004866 Phase 2 exatecan mesylate
38 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
39 Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
40 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
41 Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01267253 Phase 2 Brivanib Alaninate
42 Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00691301 Phase 2 cisplatin;pemetrexed disodium
43 Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix Completed NCT00087113 Phase 2 pemetrexed disodium
44 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
45 Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005070 Phase 2 irofulven
46 Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix Completed NCT00003017 Phase 2
47 Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer Completed NCT00002916 Phase 2
48 Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix Completed NCT00003065 Phase 2 paclitaxel;topotecan hydrochloride
49 FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Completed NCT00559377 Phase 2
50 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed NCT01026792 Phase 2 Temsirolimus

Search NIH Clinical Center for Cervical Squamous Cell Carcinoma

Genetic Tests for Cervical Squamous Cell Carcinoma

Anatomical Context for Cervical Squamous Cell Carcinoma

MalaCards organs/tissues related to Cervical Squamous Cell Carcinoma:

42
Cervix, Uterus, Lymph Node, Testes, Bone, Endothelial, T Cells

Publications for Cervical Squamous Cell Carcinoma

Articles related to Cervical Squamous Cell Carcinoma:

(show top 50) (show all 374)
# Title Authors Year
1
Association of Base Excision Repair Gene hOGG1 Ser326Cys Polymorphism with Susceptibility to Cervical Squamous Cell Carcinoma and High-Risk Human Papilloma Virus Infection in a Chinese Population. ( 30648893 )
2019
2
Genetic variants of the dUTPase-encoding gene DUT increase HR-HPV infection rate and cervical squamous cell carcinoma risk. ( 30679536 )
2019
3
Superficial spread of cervical squamous cell carcinoma to the upper genital tract and dissemination to the omentum. ( 30694584 )
2019
4
Identification of a 26-lncRNAs Risk Model for Predicting Overall Survival of Cervical Squamous Cell Carcinoma Based on Integrated Bioinformatics Analysis. ( 30698466 )
2019
5
Apparent diffusion coefficients are closely related with high-risk human papilloma virus infection in cervical squamous cell carcinoma patients. ( 30722670 )
2019
6
Effect of Electroacupuncture on Natural-Killer Cells and Tumor Size in Patients with Cervical Squamous-Cell Carcinoma: A Randomized Controlled Trial. ( 30805077 )
2019
7
A Phase 1/2 Study of Carbon Ion Radiotherapy with Concurrent Chemotherapy for Locally Advanced Uterine Cervical Squamous Cell Carcinoma (Protocol 1302). ( 30825494 )
2019
8
Long non-coding RNA-OIS1 inhibits HPV-positive, but not HPV-negative cervical squamous cell carcinoma by upregulating MTK-1. ( 30854069 )
2019
9
Association of estradiol and HPV/HPV16 infection with the occurrence of cervical squamous cell carcinoma. ( 30867796 )
2019
10
Feasibility of an ADC-based radiomics model for predicting pelvic lymph node metastases in patients with stage IB-IIA cervical squamous cell carcinoma. ( 30888846 )
2019
11
Chloride channel-3 is required for efficient tumour cell migration and invasion in human cervical squamous cell carcinoma. ( 30905432 )
2019
12
LncRNA NEF inhibits migration and invasion of HPV-negative cervical squamous cell carcinoma by inhibiting TGF-β pathway. ( 30910843 )
2019
13
Vasculogenic Mimicry Formation Is Associated with Erythropoietin Expression but Not with Erythropoietin Receptor Expression in Cervical Squamous Cell Carcinoma. ( 30915348 )
2019
14
Identification of a microRNA signature associated with survivability in cervical squamous cell carcinoma. ( 29513728 )
2018
15
Superficially invasive cervical squamous cell carcinoma metastatic to ovarian endometriotic cyst wall, a case report and brief review of the literature. ( 29848369 )
2018
16
The correlation analysis of miRNAs and target genes in metastasis of cervical squamous cell carcinoma. ( 29343084 )
2018
17
EZH2, Endothelin-1, and CD34 as Biomarkers of Aggressive Cervical Squamous Cell Carcinoma: An Immunohistochemical Study. ( 29630085 )
2018
18
A 15-long non-coding RNA signature to improve prognosis prediction of cervical squamous cell carcinoma. ( 29525275 )
2018
19
LncRNA PVT1 promotes the growth of HPV positive and negative cervical squamous cell carcinoma by inhibiting TGF-I^1. ( 29760583 )
2018
20
Which Patients With Cervical Squamous Cell Carcinoma Might Benefit From Neoadjuvant Chemotherapy? ( 29668367 )
2018
21
Caffeic Acid Targets AMPK Signaling and Regulates Tricarboxylic Acid Cycle Anaplerosis while Metformin Downregulates HIF-1I+-Induced Glycolytic Enzymes in Human Cervical Squamous Cell Carcinoma Lines. ( 29958416 )
2018
22
Association between genetic polymorphisms in the promoters of let-7 and risk of cervical squamous cell carcinoma. ( 29154871 )
2018
23
FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting I^-catenin through mRNA demethylation. ( 29315835 )
2018
24
Differentiated cervical intraepithelial neoplasia-associated invasive cervical squamous cell carcinoma as a source of major cytopathological and surgical pathological discrepancy in Papanicolaou smear screening tests. ( 29575422 )
2018
25
MiRNA373 induces cervical squamous cell carcinoma SiHa cell apoptosis. ( 29125482 )
2018
26
Towards developing a meaningful grading system for cervical squamous cell carcinoma. ( 29665326 )
2018
27
Expression of Nemo-like kinase in cervical squamous cell carcinoma: a clinicopathological study. ( 29445289 )
2018
28
E2/E6 ratio and L1 immunoreactivity as biomarkers to determine HPV16-positive high-grade squamous intraepithelial lesions (CIN2 and 3) and cervical squamous cell carcinoma. ( 29400024 )
2018
29
The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis. ( 29606483 )
2018
30
Optimal cutoff level of serum squamous cell carcinoma antigen to detect recurrent cervical squamous cell carcinoma during post-treatment surveillance. ( 29780775 )
2018
31
Radiation-Induced Uterine Carcinosarcoma after Concurrent Chemoradiotherapy for Cervical Squamous Cell Carcinoma. ( 30308682 )
2018
32
High Expression of Ubiquitin-Specific Protease 8 (USP8) Is Associated with Poor Prognosis in Patients with Cervical Squamous Cell Carcinoma. ( 30010158 )
2018
33
Laparoscopic surgery for early cervical squamous cell carcinoma and its effect on the micrometastasis of cancer cells. ( 30142804 )
2018
34
Identification of clinical tumor stages related mRNAs and miRNAs in cervical squamous cell carcinoma. ( 30149901 )
2018
35
Value of [18F]FDG PET radiomic features and VEGF expression in predicting pelvic lymphatic metastasis and their potential relationship in early-stage cervical squamous cell carcinoma. ( 30150039 )
2018
36
Clinical Value of Combining 18F-FDG PET/CT and Routine Serum Tumor Markers in The Early Detection of Recurrence Among Follow-up Patients Treated for Cervical Squamous Cell Carcinoma. ( 30210633 )
2018
37
Radiomics Analysis of Multiparametric MRI Evaluates the Pathological Features of Cervical Squamous Cell Carcinoma. ( 30230114 )
2018
38
The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy. ( 30247248 )
2018
39
Down-regulation of lncRNA snaR is correlated with postoperative distant recurrence of HPV-negative cervical squamous cell carcinoma. ( 30249756 )
2018
40
The re-awakening of hCG expression. Its role in the diagnosis of cervical squamous cell carcinoma. ( 30251729 )
2018
41
Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. ( 30254211 )
2018
42
Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab. ( 30353913 )
2018
43
Elevated CTHRC1 expression is an indicator for poor prognosis and lymph node metastasis in cervical squamous cell carcinoma. ( 30381261 )
2018
44
Methylation-Based Classification of Cervical Squamous Cell Carcinoma into Two New Subclasses Differing in Immune-Related Gene Expression. ( 30445744 )
2018
45
Use of mesothelin as a tumor-associated antigen in cervical squamous cell carcinoma. ( 30583024 )
2018
46
A Comprehensive RNA Expression Signature for Cervical Squamous Cell Carcinoma Prognosis. ( 30662454 )
2018
47
Early vulvar and umbilical incisional scar recurrence of cervical squamous cell carcinoma: Earlier than usually expected. ( 28913152 )
2017
48
Correlation Between Squamous Cell Carcinoma Antigen Level and the Clinicopathological Features of Early-Stage Cervical Squamous Cell Carcinoma and the Predictive Value of Squamous Cell Carcinoma Antigen Combined With Computed Tomography Scan for Lymph Node Metastasis. ( 28914639 )
2017
49
Characterization of the microRNA profile in early-stage cervical squamous cell carcinoma by next-generation sequencing. ( 28098890 )
2017
50
Chondrosarcoma-like metastasis from a poorly differentiated uterine cervical squamous cell carcinoma. A unique morphology and diagnostic pitfall in cytology. ( 28411397 )
2017

Variations for Cervical Squamous Cell Carcinoma

Cosmic variations for Cervical Squamous Cell Carcinoma:

9 (show top 50) (show all 189)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6917051 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4975C>G p.L1659V 16:2086857-2086857 0
2 COSM10705 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 0
3 COSM10648 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 0
4 COSM45507 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.806G>C p.S269T 17:7673814-7673814 0
5 COSM43660 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.719G>T p.S240I 17:7674244-7674244 0
6 COSM10725 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.701A>G p.Y234C 17:7674262-7674262 0
7 COSM46185 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 17:7674188-7674188 0
8 COSM10889 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.536A>G p.H179R 17:7675076-7675076 0
9 COSM10662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
10 COSM43878 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.427G>A p.V143M 17:7675185-7675185 0
11 COSM43624 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.875A>G p.K292R 17:7673745-7673745 0
12 COSM10659 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 0
13 COSM44029 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.550G>A p.D184N 17:7675062-7675062 0
14 COSM43896 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.818G>C p.R273P 17:7673802-7673802 0
15 COSM10749 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.830G>T p.C277F 17:7673790-7673790 0
16 COSM43662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.868C>A p.R290S 17:7673752-7673752 0
17 COSM45259 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.301A>T p.K101* 17:7676068-7676068 0
18 COSM11483 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.848G>A p.R283H 17:7673772-7673772 0
19 COSM11356 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.726C>G p.C242W 17:7674237-7674237 0
20 COSM6917055 TOP1 cervix,NS,carcinoma,squamous cell carcinoma c.1897C>T p.Q633* 20:41118243-41118243 0
21 COSM6933657 TGFBR2 cervix,NS,carcinoma,squamous cell carcinoma c.931G>T p.E311* 3:30672114-30672114 0
22 COSM6918339 TET2 cervix,NS,carcinoma,squamous cell carcinoma c.2659G>A p.E887K 4:105236601-105236601 0
23 COSM6906292 TENT5C cervix,NS,carcinoma,squamous cell carcinoma c.722G>T p.G241V 1:117623590-117623590 0
24 COSM25844 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.647C>T p.S216F 19:1220630-1220630 0
25 COSM3734673 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.597G>C p.E199D 19:1220505-1220505 0
26 COSM29464 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.169G>T p.E57* 19:1207082-1207082 0
27 COSM29465 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.320A>G p.H107R 19:1218446-1218446 0
28 COSM6977087 SPOP cervix,NS,carcinoma,squamous cell carcinoma c.962C>T p.A321V 17:49601883-49601883 0
29 COSM421102 ROS1 cervix,NS,carcinoma,squamous cell carcinoma c.1682C>T p.P561L 6:117389427-117389427 0
30 COSM6977085 RB1 cervix,NS,carcinoma,squamous cell carcinoma c.1630A>T p.R544* 13:48381378-48381378 0
31 COSM6910533 RAD54L cervix,NS,carcinoma,squamous cell carcinoma c.1900C>T p.R634C 1:46277847-46277847 0
32 COSM6977079 RAD50 cervix,NS,carcinoma,squamous cell carcinoma c.432G>C p.E144D 5:132587654-132587654 0
33 COSM6977082 RAD21 cervix,NS,carcinoma,squamous cell carcinoma c.1702C>T p.Q568* 8:116848948-116848948 0
34 COSM6977083 RAD21 cervix,NS,carcinoma,squamous cell carcinoma c.1681C>T p.Q561* 8:116848969-116848969 0
35 COSM6975050 PTPRS cervix,NS,carcinoma,squamous cell carcinoma c.5630C>G p.S1877C 19:5208249-5208249 0
36 COSM6917045 PTPRD cervix,NS,carcinoma,squamous cell carcinoma c.1693G>A p.E565K 9:8504390-8504390 0
37 COSM5089 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.517C>T p.R173C 10:87952142-87952142 0
38 COSM5945791 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.65A>G p.D22G 10:87864534-87864534 0
39 COSM4822061 POLE cervix,NS,carcinoma,squamous cell carcinoma c.865G>A p.E289K 12:132676590-132676590 0
40 COSM6937072 PIK3R1 cervix,NS,carcinoma,squamous cell carcinoma c.1859A>G p.D620G 5:68296215-68296215 0
41 COSM43062 PIK3CG cervix,NS,carcinoma,squamous cell carcinoma c.53G>A p.R18Q 7:106867614-106867614 0
42 COSM5878662 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1579G>A p.D527N 3:179218249-179218249 0
43 COSM773 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3129G>T p.M1043I 3:179234286-179234286 0
44 COSM763 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 3:179218303-179218303 0
45 COSM760 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>A p.E542K 3:179218294-179218294 0
46 COSM12584 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1357G>A p.E453K 3:179210291-179210291 0
47 COSM7351397 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.2924G>A p.R975K 3:179230364-179230364 0
48 COSM27134 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3130A>G p.N1044D 3:179234287-179234287 0
49 COSM775 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3140A>G p.H1047R 3:179234297-179234297 0
50 COSM17442 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>C p.E542Q 3:179218294-179218294 0

Copy number variations for Cervical Squamous Cell Carcinoma from CNVD:

7 (show all 38)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 191444 5 1 15100000 Gain PDCD6 Cervical squamous cell carcinoma
2 191466 5 1 18500000 Gain POLS Cervical squamous cell carcinoma
3 191467 5 1 18500000 Gain SDHA Cervical squamous cell carcinoma
4 191468 5 1 18500000 Gain SRD5A1 Cervical squamous cell carcinoma
5 191624 5 1 42400000 Gain RPL37 Cervical squamous cell carcinoma
6 191625 5 1 42400000 Gain SKP2 Cervical squamous cell carcinoma
7 191627 5 1 42400000 Gain SLC1A3 Cervical squamous cell carcinoma
8 191642 5 1 4400000 Gain IRX2 Cervical squamous cell carcinoma
9 191643 5 1 4400000 Gain NDUFS6 Cervical squamous cell carcinoma
10 191644 5 1 4400000 Gain TERT Cervical squamous cell carcinoma
11 191646 5 1 4400000 Gain TRIP13 Cervical squamous cell carcinoma
12 191726 5 1 8200000 Gain IRX4 Cervical squamous cell carcinoma
13 195451 5 15100000 18500000 Gain ANKH Cervical squamous cell carcinoma
14 195452 5 15100000 18500000 Gain ZNF622 Cervical squamous cell carcinoma
15 195453 5 15100000 23300000 Gain MYO10 Cervical squamous cell carcinoma
16 195454 5 15100000 29300000 Gain BASP1 Cervical squamous cell carcinoma
17 198725 5 29300000 34400000 Gain DROSHA Cervical squamous cell carcinoma
18 198726 5 29300000 34400000 Gain GOLPH3 Cervical squamous cell carcinoma
19 198727 5 29300000 34400000 Gain MTMR12 Cervical squamous cell carcinoma
20 198728 5 29300000 34400000 Gain SUB1 Cervical squamous cell carcinoma
21 199076 5 34400000 38500000 Gain DNAJA5 Cervical squamous cell carcinoma
22 199078 5 34400000 38500000 Gain LMBRD2 Cervical squamous cell carcinoma
23 199079 5 34400000 38500000 Gain NIPBL Cervical squamous cell carcinoma
24 199080 5 34400000 38500000 Gain RAD1 Cervical squamous cell carcinoma
25 199082 5 34400000 38500000 Gain TARS Cervical squamous cell carcinoma
26 199083 5 34400000 38500000 Gain WDR70 Cervical squamous cell carcinoma
27 199384 5 38500000 42400000 Gain NUP155 Cervical squamous cell carcinoma
28 199385 5 38500000 42400000 Gain OXCT1 Cervical squamous cell carcinoma
29 199684 5 42400000 45800000 Gain CCL28 Cervical squamous cell carcinoma
30 199685 5 42400000 45800000 Gain FBXO4 Cervical squamous cell carcinoma
31 199686 5 42400000 45800000 Gain PAIP1 Cervical squamous cell carcinoma
32 199689 5 42400000 47700000 Gain ZNF131 Cervical squamous cell carcinoma
33 199835 5 4400000 6000000 Gain KIAA0947 Cervical squamous cell carcinoma
34 202451 5 8200000 15100000 Gain CCT5 Cervical squamous cell carcinoma
35 202452 5 8200000 15100000 Gain DAP Cervical squamous cell carcinoma
36 202454 5 8200000 15100000 Gain MARCH-VI Cervical squamous cell carcinoma
37 202462 5 8200000 23300000 Gain ZFYVE16 Cervical squamous cell carcinoma
38 202464 5 8200000 45800000 Gain OSRF Cervical squamous cell carcinoma

Expression for Cervical Squamous Cell Carcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Cervical Squamous Cell Carcinoma patients vs. healthy controls: 35 (show all 33)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CRNN cornulin Uterus - 5.62 0.000
2 KRT1 keratin 1, type II Uterus - 5.32 0.000
3 UPK1A uroplakin 1A Uterus - 4.79 0.000
4 MAL mal, T-cell differentiation protein Uterus - 4.73 0.000
5 KRT4 keratin 4, type II Uterus - 4.45 0.000
6 SPRR3 small proline-rich protein 3 Uterus - 4.43 0.000
7 DSG1 desmoglein 1 Uterus - 4.27 0.000
8 CDKN2A cyclin-dependent kinase inhibitor 2A Uterus + 4.21 0.000
9 CRISP3 cysteine-rich secretory protein 3 Uterus - 4.13 0.000
10 CRCT1 cysteine-rich C-terminal 1 Uterus - 3.92 0.000
11 SPINK5 serine peptidase inhibitor, Kazal type 5 Uterus - 3.67 0.000
12 SLURP1 secreted LY6/PLAUR domain containing 1 Uterus - 3.54 0.000
13 APOC1 apolipoprotein C-I Uterus + 3.53 0.000
14 HOPX HOP homeobox Uterus - 3.51 0.000
15 EDN3 endothelin 3 Uterus - 3.48 0.000
16 FANCI Fanconi anemia, complementation group I Uterus + 3.42 0.000
17 SYNGR3 synaptogyrin 3 Uterus + 3.41 0.000
18 CRYAB crystallin, alpha B Uterus - 3.39 0.000
19 KRT13 keratin 13, type I Uterus - 3.35 0.004
20 MCM5 minichromosome maintenance complex component 5 Uterus + 3.31 0.000
21 ALOX12 arachidonate 12-lipoxygenase Uterus - 3.26 0.000
22 PPP1R3C protein phosphatase 1, regulatory subunit 3C Uterus - 3.23 0.000
23 SCEL sciellin Uterus - 3.19 0.000
24 NTS neurotensin Uterus + 3.19 0.006
25 NUSAP1 nucleolar and spindle associated protein 1 Uterus + 3.17 0.000
26 IVL involucrin Uterus - 3.14 0.000
27 IL1R2 interleukin 1 receptor, type II Uterus - 3.14 0.000
28 CFD complement factor D (adipsin) Uterus - 3.13 0.000
29 SOSTDC1 sclerostin domain containing 1 Uterus - 3.08 0.000
30 ESR1 estrogen receptor 1 Uterus - 3.06 0.000
31 PAMR1 peptidase domain containing associated with muscle regeneration 1 Uterus - 3.06 0.000
32 ENDOU endonuclease, polyU-specific Uterus - 3.04 0.000
33 HOXC6 homeobox C6 Uterus + 3.01 0.000
Search GEO for disease gene expression data for Cervical Squamous Cell Carcinoma.

Pathways for Cervical Squamous Cell Carcinoma

GO Terms for Cervical Squamous Cell Carcinoma

Cellular components related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.83 CDH1 CDKN2A CTNNB1 TP53 TP63
2 regulation of apoptotic process GO:0042981 9.62 CTNNB1 DAPK1 TP53 TP63
3 Ras protein signal transduction GO:0007265 9.43 CDKN2A RASSF1 TP53
4 regulation of myelination GO:0031641 9.4 CTNNB1 TYMP
5 replicative senescence GO:0090399 9.37 CDKN2A TP53
6 entry of bacterium into host cell GO:0035635 9.16 CDH1 CTNNB1
7 cranial skeletal system development GO:1904888 8.96 CTNNB1 TP63
8 cellular response to indole-3-methanol GO:0071681 8.62 CDH1 CTNNB1

Molecular functions related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.8 CDKN2A CTNNB1 TP53

Sources for Cervical Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....